Author:
Wu Linxuan,Niu Xin,Brunelli Marisa Kaitlin,Mugwanya Kenneth K.
Funder
National Institute of Mental Health of the US National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral Prophylaxis for HIV-1 Prevention among Heterosexual Men and Women. N Engl J Med. 2012;367(5):399–410.
2. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.
3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Engl J Med. 2010;363(27):2587–99. https://doi.org/10.1056/NEJMoa1011205.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New Engl J Med. 2012;367(5):423–34. https://doi.org/10.1056/NEJMoa1110711.
5. Antiretroviral TS. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. World Health Organization. 2015 [cited 2023 Aug 2]; Available from: https://www.who.int/publications/i/item/9789241509565